Antisense oligonucleotides and their use for treating Pendred syndrome
US11312959B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 11, 2021 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Feb 11, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that prevent or reduce exon 8 skipping in the SLC26A4 gene during pre-mRNA splicing, and their use in the treatment of Pendred Syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.